

285 Psychotropic Medications and Rapid Tranquilization

REFERENCES

- Martel M, Sterzinger A, Miner J, et al: Management of acute undifferentiated agitation in the emergency department: a randomized, double-blind trial of droperidol, ziprasidone, and midazolam. *Acad Emerg Med* 12(12): 1167, 2005.
- Yildiz A, Sachs G, Turgay A: Pharmacologic management of agitation in emergency settings. *Emerg Med J* 20(4): 339, 2003.
- Battaglia J, Moss S, Rush J, et al: Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. *Am J Emerg Med* 15(4): 335, 1997.
- De Fruyt J, Demyttenaere K: Rapid tranquilization: new approaches in the emergency treatment of behavioral disturbances. *Eur Psychol* 19(5): 243, 2004.
- Martel M, Gray R: Novel route of sedative administration in the management of acute undifferentiated agitation in the emergency department. *Ann Emerg Med* 48(4): 125, 2006.
- Hick JL, Ho J: Ketamine chemical restraint to facilitate rescue of a combative "jumper." *Prehosp Emerg Care* 9: 85, 2005.
- Available at: <http://www.cms.hhs.gov/CFCsAndCoPs/downloads/finalpatientrightsrule.pdf>. Accessed April 27, 2008.
- Yap YG, Camm AJ: Drug induced QT prolongation and torsades de pointes. *Heart* 89(11): 1363, 2003.
- Roden DM: Drug-induced prolongation of the QT interval. *N Engl J Med* 350(10): 1013, 2004.
- Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. Available at: <http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm053171.htm>. Accessed March 15, 2010.
- Drolet B, Vincent R, Rail J, et al: Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. *J Pharmacol Exp Ther* 288: 1261, 1999.
- Suessbrich J, Schonherr R, Heinemann SH, et al: The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in *Xenopus* oocytes. *Br J Pharmacol* 120: 968, 1997.
- Luna B, Feinglos MN: Drug-induced hyperglycemia. *JAMA* 286: 1945, 2001.
- Depression. National Institutes of Health. Available at: <http://www.nimh.nih.gov>. Accessed May 2, 2008.
- Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020415s018,021208s009lbl.pdf. Accessed March 15, 2010.
- Blum D, Maldonado J, Meyer E, Lansberg M: Delirium following abrupt discontinuation of fluoxetine. *Clin Neurol Neurosurg* 110 (1): 69, 2008.
- Dvir Y, Smallwood P: Serotonin syndrome: a complex but easily avoidable condition. *Gen Hosp Psychiatry* 30(3): 284, 2008.
- Stone MB, Jones ML: Clinical review: relationship between antidepressant drugs and suicidality in adults, in *Overview for December 13 meeting of Psychopharmacologic Drugs Advisory Committee (PDAC)*. Silver Spring, MD, U.S. Food and Drug Administration, November 2006.
- Levenson M, Holland C: Statistical evaluation of suicidality in adults treated with antidepressants, in *Overview for December 13 meeting of Psychopharmacologic Drugs Advisory Committee (PDAC)*. Silver Spring, MD, U.S. Food and Drug Administration, November 2006.
- Cipriani A, Geddes JR, Furukawa TA, Barbui C: Metareview of short-term effectiveness and safety of antidepressants for depression; an evidence-based approach to inform clinical practice. *Can J Psychiatry* 52(9): 553, 2007.
- Beasley CM, Ball SG, Nilsson ME, et al: Fluoxetine and adult suicidality revisited; an updated meta-analysis using expanded data sources from placebo controlled trials. *J Clin Psychopharmacol* 27(6): 682, 2007.
- Saarto T, Wiffen ST: Antidepressants for neuropathic pain. *Cochrane Database Syst Rev* 4: CD005454, 2007. Available at: <http://www.Cochrane.org/reviews/en/ab005454.html>. Accessed April 2, 2008.
- FDA approves Emsam (selegiline) as first drug patch for depression. Press release. U.S. Food and Drug Administration; February 28, 2006. Available at: <http://www.fda.gov/bbs/topics/NEWS/2006/NEW01326.html>. Accessed April 28, 2008.
- Dhillon S, Yang LP, Curran MP: Bupropion: a review of its use in the management of major depression. *Drugs* 68(5): 653, 2008.
- Ozyalcin S, Talu G, Kiziltan E, et al: The efficacy and safety of venlafaxine in the prophylaxis of migraine. *Headache* 45(2): 144, 2005.
- Effexor (medicine data sheet). Madison, NJ, Wyeth Pharmaceuticals; 2006.

USEFUL WEB RESOURCES

- Medicare and Medicaid Programs; Hospital Conditions of Participation: Patients' Rights, Department of Health and Human Services (*Federal Register*, December 8, 2006)—<http://www.cms.hhs.gov/CFCsAndCoPs/downloads/finalpatientrightsrule.pdf>
- Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances, FDA Public Health Advisory—<http://www.fda.gov/drugs/drugsafety/PublicHealthAdvisories/ucm053171.htm>
- Depression, National Institutes of Health—<http://www.nimh.nih.gov>
- Antidepressant Use in Children, Adolescents, and Adults, FDA public health advisory—<http://www.fda.gov/cder/drug/antidepressants/default.htm>
- Antidepressants for Neuropathic Pain, Cochrane reviews, the Cochrane Collaboration—<http://www.Cochrane.org/reviews/en/ab005454.html>
- Toxicity of tricyclic antidepressants, eMedicine—<http://www.emedicine.com/ped/topic2714.htm>
- FDA Approves Emsam (Selegiline) as First Drug Patch For Depression, press release—<http://www.fda.gov/bbs/topics/NEWS/2006/NEW01326.html>